NASDAQ:XOMAP XOMA (XOMAP) Stock Price, News & Analysis $26.28 -0.43 (-1.59%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About XOMA Stock (NASDAQ:XOMAP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XOMA alerts:Sign Up Key Stats Today's Range$26.23▼$26.2350-Day Range$25.50▼$27.1952-Week Range$24.96▼$30.00Volume217 shsAverage Volume1,617 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield8.22%Price TargetN/AConsensus RatingN/A Company Overview XOMA Corporation (NASDAQ:XOMAP) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and delivering therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. The company leverages its proprietary protein engineering and antibody discovery platforms to create novel biologic candidates designed to modulate key immune pathways. XOMA’s research focuses on targets implicated in conditions such as systemic lupus erythematosus, rheumatoid arthritis and other chronic inflammatory disorders. XOMA’s pipeline includes multiple antibody candidates at various stages of development, ranging from lead optimization to early clinical trials. The company employs structure‐guided design and high‐throughput screening to enhance the specificity and potency of its product candidates. XOMA also pursues strategic partnerships to co‐develop assets and expand its reach into new therapeutic areas, collaborating with academic institutions and industry leaders to accelerate progress from preclinical discovery to human studies. Founded in 1981 and headquartered in Berkeley, California, XOMA has driven innovation in protein therapeutics for more than three decades. The company operates research facilities in the San Francisco Bay Area and maintains relationships with contract development and manufacturing organizations worldwide. Under the leadership of President and Chief Executive Officer Paul Rubin, XOMA continues to build on its legacy of antibody discovery, with a focus on bringing first‐in‐class and best‐in‐class therapies to patients in need of novel treatments for immune‐mediated diseases.AI Generated. May Contain Errors. Read More Receive XOMAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XOMAP Stock News HeadlinesShort Interest in XOMA Co. (NASDAQ:XOMAP) Grows By 1,325.0%September 13 at 2:55 AM | americanbankingnews.comXOMA Co. (NASDAQ:XOMAP) Short Interest UpdateSeptember 7, 2025 | americanbankingnews.comApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors only care about AI, and Apple still has no clear roadmap — which is why Porter Stansberry says the real upside isn’t in Apple or Nvidia, but in the “picks and shovels” companies powering the AI boom, from energy to components to networks.September 14 at 2:00 AM | Porter & Company (Ad)BioInvent International AB: Interim Report January - June 2025August 26, 2025 | finance.yahoo.comLAVA Therapeutics N.V.: LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deXOMA-Backed XenoTherapeutics to Acquire Essa PharmaJuly 14, 2025 | marketwatch.comXOMA To Acquire Turnstone Biologics For $0.34/Shr Plus Contingent Value Right - NasdaqJune 29, 2025 | nasdaq.comResults: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 16, 2025 | finance.yahoo.comSee More Headlines XOMAP Stock Analysis - Frequently Asked Questions How have XOMAP shares performed this year? XOMA's stock was trading at $25.88 at the start of the year. Since then, XOMAP shares have increased by 1.5% and is now trading at $26.2740. How do I buy shares of XOMA? Shares of XOMAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 7/15 Dividend7/03/2025Ex-Dividend for 7/15 Dividend7/03/2025Dividend Payable7/15/2025Today9/13/2025Next Earnings (Estimated)11/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XOMAP CIK791908 Webwww.xoma.com Phone510-204-7200FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$12.77 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:XOMAP) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe End of Elon Musk…?While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.